3,5-Di-O-caffeoyl-epi-quinic acid from the leaves and stems of Erigeron annuus inhibits protein glycation, aldose reductase, and cataractogenesis.
In our ongoing project directed toward the discovery of novel treatments for diabetic complications from herbal medicines, sixteen compounds including three caffeoylquinic acids and four flavonoids were isolated from an EtOAc-soluble extract of the stems and leaves of Erigeron annuus. All the isolates were evaluated in vitro for inhibitory activity on the formation of advanced glycation end products (AGEs) and rat lens aldose reductase (RLAR). Of these, 3,5-di-O-caffeoyl-epi-quinic acid (3) exhibited the most potent inhibitory activity in both the AGEs and aldose reductase (AR) assays. Compound 3 markedly reduced AGEs-bovin serum albumin (BSA) cross-linking in a dose-dependent manner. Furthermore, opacity of lenses was significantly prevented when they were treated with 3 in an ex vivo experiment.
Jang
Dae Sik
DS
Diabetic Complications Research Center, Division of Traditional Korean Medicine (TKM) Integrated Research, Korea Institute of Oriental Medicine, 483 Expo-ro, Yuseong-gu, Daejeon 305-811, Korea.
Yoo
Nam Hee
NH
Kim
Nan Hee
NH
Lee
Yun Mi
YM
Kim
Chan-Sik
CS
Kim
Junghyun
J
Kim
Joo-Hwan
JH
Kim
Jin Sook
JS
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D002386:Cataract / Q000201:enzymology / Q000378:metabolism* / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D049919:Erigeron / Q000737:chemistry; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors* / Q000378:metabolism; D007908:Lens, Crystalline / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009005:Monosaccharides / Q000494:pharmacology* / Q000627:therapeutic use; D009924:Organ Culture Techniques; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use; D018515:Plant Leaves / Q000737:chemistry; D018547:Plant Stems / Q000737:chemistry; D011801:Quinic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley
C500585:3,5-di-O-(E)-caffeoylquinic acid; D017127:Glycation End Products, Advanced; D009005:Monosaccharides; D010936:Plant Extracts; D011801:Quinic Acid; D000449:Aldehyde Reductase